Skip to search formSkip to main contentSkip to account menu

TRU 016

Known as: TRU-016 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Otlertuzumab (TRU‐016) is a humanized anti‐CD37 protein therapeutic that triggers direct caspase‐independent apoptosis of… 
2014
2014
SummaryPurpose CD37 is cell surface tetraspanin present on normal and malignant B cells. Otlertuzumab (TRU-016) is a novel… 
Review
2014
Review
2014
Introduction: Immunotherapy using mAbs is a safe and effective method for the treatment of chronic lymphocytic leukemia (CLL) and… 
2013
2013
Background CD37 is a tetraspanin protein expressed on the surface of normal and transformed B-cells across a wide range of… 
Review
2013
Review
2013
Monoclonal antibodies (mAbs) - rituximab, ofatumumab and alemtuzumab - have been approved for use in the therapy of chronic… 
2011
2011
Abstract 1792 Background: CD37 is a tetraspanin protein expressed on the surface of normal and transformed B-cells across a wide… 
2010
2010
Abstract 56 Background: CD37 is a member of the tetraspanin superfamily of molecules which are implicated in diverse processes… 
2010
2010
Abstract 3931 Background: CD37 is a 50–55 kDa heavily glycosylated member of the tetraspanin superfamily of molecules. This cell… 
2009
2009
8571 Background: TRU-016, a single chain anti-CD37 Fc fusion molecule has been shown to display pro-apoptotic and Fc-dependent… 
2009
2009
Abstract 3424 Poster Board III-312 Background CD37 is a tetraspanin family member expressed predominantly on normal and…